Studieoverzicht
Study name: Tropion-Lung 08
Histology | NSCLC |
---|---|
Tumor stage | Stage IV |
Host / recruiting sites | LUMC |
Enrollment | Recruiting |
Therapy line | First line (1L) |
Design |
Gerandomiseerde, fase 3 studie |
Intervention | Dato-DXd (Datopotamab Deruxtecan) icm Pembrolizumab vs Pembrolizumab |
Key outcome parameters | PFS, OS |
Key inclusion criteria | Stadium IIIB-IV NSCLC zonder driver mutatie met PD-L1 ≥50%, geen eerdere systeemtherapie |
Key exclusion criteria | Symptomatische CNS metastasen Co-morbiditeit oa LVEF <50%, ILD, equivalent >10mg prednison |
Contact information | Log in voor de contactinformatie |